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Cystic fibrosis transmembrane conductance regulator (CFTR) is a polytopic membrane protein that functions as a Cl
channel and consists of two membrane spanning domains (MSDs), two cytosolic nucleotide binding domains (NBDs),
and a cytosolic regulatory domain. Cytosolic 70-kDa heat shock protein (Hsp70), and endoplasmic reticulum-localized
calnexin are chaperones that facilitate CFTR biogenesis. Hsp70 functions in both the cotranslational folding and
posttranslational degradation of CFTR. Yet, the mechanism for calnexin action in folding and quality control of CFTR is
not clear. Investigation of this question revealed that calnexin is not essential for CFTR or CFTRF508 degradation. We
identified a dependence on calnexin for proper assembly of CFTR’s membrane spanning domains. Interestingly, efficient
folding of NBD2 was also found to be dependent upon calnexin binding to CFTR. Furthermore, we identified folding
defects caused by deletion of F508 that occurred before and after the calnexin-dependent association of MSD1 and MSD2.
Early folding defects are evident upon translation of the NBD1 and R-domain and are sensed by the RMA-1 ubiquitin
ligase complex.
INTRODUCTION
Cystic fibrosis transmembrane conductance regulator
(CFTR) is a membrane glycoprotein that is localized to the
apical surface of epithelial cells that line ducts of glands and
airways. CFTR functions as an ATP-gated Cl channel that
is critical for proper hydration of the mucosal layer that lines
lung airways (Welsh and Smith, 1993). Individuals who
inherit two mutant forms of CFTR have exceedingly viscous
mucous and, due to chronic lung infections, develop cystic
fibrosis and often die from lung failure. CFTR is a member of
the ATP-binding cassette (ABC) transporter superfamily
(Hyde et al., 1990) and is a 1480-amino acid protein that
contains two membrane spanning domains (MSDs), MSD1
and MSD2; two cytosolic nucleotide binding domains
(NBDs), NBD1 and NBD2; and a regulatory (R) domain
(Riordan et al., 1989). The proper folding and assembly of
CFTR subdomains in the endoplasmic reticulum (ER) is
required for CFTR to engage the COPII machinery and be
packaged into vesicles for transport to the plasma mem-
brane (Kopito, 1999; Wang et al., 2004). The folding pathway
of this complex polytopic membrane protein has been a
topic of great interest, because misfolding results in prema-
ture recognition of CFTR by the ER quality control system
(ERQC) and degradation by the ubiquitin proteasome sys-
tem (Skach, 2000). In fact, the most common disease-causing
mutation of CFTR, F508CFTR, results in almost complete
degradation of the protein by the ERQC system, which gives
rise to a loss of function phenotype and lung disease (Ward
and Kopito, 1994).
The assembly of CFTR into an ion channel is complicated
because it requires the coordinated folding and assembly of
its membrane and cytoplasmic domains into a functional
unit (Du et al., 2005; Riordan, 2005; Cui et al., 2007). CFTR is
a modular protein, and its domains can collapse to a pro-
tease-resistant conformation independently (Zhang et al.,
1998). Yet, structures of related ABC transporter family
members suggest that assembly of CFTR to an active con-
formation is a cooperative process that is dependent upon
cross-contact formation between its N- and C-terminal mem-
brane and cytosolic domains (Dawson and Locher, 2006;
Mendoza and Thomas, 2007; Serohijos et al., 2008). Forma-
tion of a CFTR structure that can pass quality control occurs
in cotranslational and posttranslational steps that are pro-
posed to involve critical interactions between solvent-ex-
posed surfaces of NBD1 and MSD2 and similar interactions
between NBD2 and MSD1 (Serohijos et al., 2008). A fragment
of CFTR that contains MSD1, NBD1, the R-domain, and
MSD2 (CFTR 1-1172) can fold to a conformation that can
escape the ER quality control system and traffic to the
plasma membrane in which it exhibits ATP-gated channel
activity (Cui et al., 2007). Thus, it is assumed that MSD1,
NBD1, the R-domain, and MSD2 are folded and assembled
cotranslationally, with the folding and subsequent assembly
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of NBD2 into a complex, with the remainder of the protein
occurring posttranslationally.
F508 of CFTR is located on the solvent-exposed surface of
NBD1 (Lewis et al., 2004; Thibodeau et al., 2005), and the
crystal structures of bacterial ABC transporters suggest that
it makes contacts with cytosolic surface loops on MSD2 that
are critical for stabilization of CFTR structure (Dawson and
Locher, 2006; Serohijos et al., 2008). This supposition is sup-
ported by the observation that the F508 mutation disrupts
assembly of CFTR 1-1172 (Cui et al., 2007) and makes similar
CFTR fragments susceptible to cotranslational recognition
by the ER-associated ubiquitin ligase RMA1 (Younger et al.,
2006). NBD2 is the last domain on CFTR that is synthesized,
and its folding and assembly into a complex with amino-
terminal regions of CFTR seems to be slow and thus occur
posttranslationally (Du et al., 2005). Deletion of F508 hinders
the folding of NBD2, but whether this occurs as a result of
improper interaction of F508 NBD1 with NBD2 or global
defects in CFTR assembly is not clear (Du et al., 2005; Cui et
al., 2007).
The folding and assembly of CFTR is not a spontaneous
process, and some of the same chaperones that are involved
in the selection of misfolded CFTR for degradation are also
required for CFTR folding. The 40-kDa heat shock protein
(Hsp40) Hdj2 is farnesylated and localized to the cytoplas-
mic face of the ER in which it binds CFTR translation inter-
mediates to facilitate aspects of its cotranslational folding
(Meacham et al., 1999). Yet, severalfold more Hdj2 is found
in association with CFTRF508, so Hdj2 may also participate
in the selection of misfolded CFTR for degradation by the
Hsp70/CHIP E3 ubiquitin ligase complex (Meacham et al.,
2001). Hsp90 is required for CFTR biogenesis (Loo et al.,
1998), and cellular depletion of the Hsp90 cochaperone Aha1
enhances CFTR folding (Wang et al., 2006); yet, the step
where Hsp90 acts in the CFTR folding pathway is not clear.
The ER lumenal chaperone calnexin forms transient com-
plexes with the ER localized and immaturely glycosylated
B-form of CFTR (Pind et al., 1994), but mechanistic details of
calnexin function in CFTR biogenesis also remain to be
elucidated.
Studies with CFTR assembly intermediates indicate that
Hsp70 can bind CFTR at co- and posttranslational stages of
its biogenesis (Meacham et al., 1999), but no data are avail-
able to describe the temporal relationship between Hsp70
and calnexin function in CFTR biogenesis. Calnexin binds
N-linked glycans, and two such glycosylation sites are
found on CFTR in extracellular loop 4 in MSD2 (Cheng et al.,
1990; Farinha and Amaral, 2005). Knockdown of calnexin
leads a large portion of nascent CFTR to misfold, but why
calnexin is required for CFTR folding is not clear (Farinha
and Amaral, 2005; Okiyoneda et al., 2008). In addition, anal-
ysis of calnexin’s role in degradation of misfolded CFTR and
CFTRF508 has provided mixed results. Overexpression of
calnexin results in the accumulation of F508 CFTR in the
ER (Okiyoneda et al., 2004), but RNA interference (RNAi)-
mediated decrease of calnexin levels or deletion of the cal-
nexin gene does not inhibit degradation of wild-type (WT)
or F508 CFTR (Farinha and Amaral, 2005; Okiyoneda et al.,
2008).
In this study, we sought to define the steps in CFTR
folding and degradation that are catalyzed by calnexin. In
addition, we examined the temporal relationship between
folding defects caused by disease mutations such as F508
to calnexin-dependent folding reactions. Finally, by further
refining the steps in the CFTR folding pathway we hoped to
clarify the events that lead to recognition of misfolded CFTR
by the ERQC machinery. To accomplish these goals, we
examined the influence that castanospermine (CAS), an in-
hibitor of the ER glucosidase I and II enzymes that process
N-linked oligosaccharides to a form that can be recognized
by calnexin, had on CFTR folding and degradation (Ham-
mond et al., 1994). We found that calnexin plays a critical
role in the stabilization of the MSD2 domain of CFTR. Inhi-
bition of calnexin binding blocked CFTR folding at a stage
where MSD1 and MSD2 normally associate. Disruption of
this calnexin-dependent reaction also caused a downstream
defect in the folding of C-terminal NBD2. Similarly, intro-
duction of the F508 mutation caused both early and late
folding defects, with the early defects being monitored by
the RMA-1ubiquitin ligase complex.
MATERIALS AND METHODS
Plasmids, Antibodies, and Reagents
CFTR expression plasmids of pcDNA3.1-CFTR and pcDNA3.1-F508-CFTR
have been described previously (Meacham et al., 1999), and CFTR constructs
representing biogenic intermediates were made by use of QuikChange (Strat-
agene, La Jolla, CA) to introduce stop codons after the indicated amino acid.
Antibodies used in this study were as follows: mouse monoclonal -CFTR
MM13-4 (N-terminal tail epitope) and -CFTR M3A7 (NBD2 epitope) were
from Millipore (Billerica, MA); rabbit polyclonal -Hsp/c70 (SPA-757) and
rabbit polyclonal -calnexin (SPA-860) were from Nventa Biopharmaceuticals
(San Diego, CA); mouse -tubulin was purchased from Sigma (T9026); and
rabbit -Derlin-1 (PM018) was purchased from MBL International (Woburn,
MA). Polyclonal -CFTR was generated against a glutathione transferase
(GST) fusion protein that contained residues 1–79 of CFTR and was a gift from
Dr. K. Kirk (Department of Physiology and Biophysics, University of Ala-
bama-Birmingham). CAS was purchased from Sigma and used at a final
concentration of 5 mM to inhibit glucosidase I and II. Brefeldin A (BFA) was
from Sigma and used at a final concentration of 10 g/ml.
Cell Culture and Transfection
Human embryonic kidney (HEK)293 cells were from Stratagene and were
maintained in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum (HyClone Labo-
ratories, Logan, UT) and antibiotics (100 U/ml penicillin and 100 g/ml
streptomycin; Invitrogen) at 37°C in an atmosphere of 5% CO2. Cell transfec-
tions were performed using Effectene reagent (QIAGEN, Valencia, CA)
with 1 g pcDNA3.1-F508-CFTR, pcDNA3.1-CFTR, pcDNA3.1-CFTR642X
pcDNA3.1-CFTR653X, pcDNA3.1-CFTR673X, pcDNA3.1-CFTR837X, pcDNA3.1-
CFTR1162X, pcDNA3.1CFTR1172X, or pcDNA3.1-CFTR837–1480 for one six-
well for Western Blot, pulse chase, or immunoprecipitation.
Coexpression of CFTR Halves
Cells were transfected with pcDNA3.1-CFTR837X (1 g) and pcDNA3.1-
CFTR837-1480 (1 g), individually or in combination. Reactions were bal-
anced with pcDNA3.1 such that all transfections were performed with equal
microgram quantities of DNA. Where indicated, brefeldin A (10 g/ml) or
CAS (5 mM) was added to the media 5 h after transfection or N-acetyl-L-
leucinyl-L-leucinyl-L-norleucinal (ALLN) (200 M) was added 18 h after
transfection. Twenty-four hours after transfection, cells were harvested with
citric saline, diluted in 2 sample buffer (100 mM Tris, pH 6.8, 4% SDS, 20%
glycerol, and 0.1% bromphenol blue), sonicated for 10 s, and warmed to 37°C
for 10 min before loading on 10% SDS-PAGE gels. Proteins were transferred
to nitrocellulose using a mini gel wet transfer apparatus (Bio-Rad, Hercules,
CA). Blots were blocked in blocking buffer containing 10% fat-free milk and
0.1% Triton-X 100 in phosphate-buffered saline (PBS) and probed with mono-
clonal -CFTR N-terminal tail (MM13-4 1:1000 dilution) or -CFTR NBD2
(M3A7 1:1000 dilution). -Tubulin (Sigma) or -Derlin-1 (MBL International)
was used to indicate loading controls.
Analysis of CFTR Folding and Degradation
The fate of nascent CFTR and CFTRF508 was analyzed by pulse chase as
described below. Twenty-four hours after transfection, cells were preincu-
bated for 1 h with 5 mM CAS in DMEM where indicated, starved in methi-
onine-free minimal essential medium (Sigma) for 20 min, pulse labeled for 30
min with [35S]methionine (100 Ci/6-well; 1200 Ci/mmol; MP Biomedicals,
Irvine, CA) and then chased for the indicated amount of time. Cells were then
washed twice in PBS and lysed in radioimmunoprecipitation assay (RIPA)
buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.2% SDS, and 50 mM
HEPES, pH 7.4) freshly supplemented with 1 mM phenylmethylsulfonyl
fluoride and Complete Protease Inhibitor cocktail (Roche Diagnostics, India-
napolis, IN). Lysates were precleared with 2% Pansorbin cells (Calbiochem,
San Diego, CA) for 15 min. Radiolabeled CFTR was then immunoprecipitated
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by incubation with rabbit polyclonal -CFTR antibody directed against the N
terminus (provided as a kind gift from Dr. K. Kirk) and protein G beads
sequentially for 1 h each at 4°C, washed three times with RIPA buffer, and
eluted with 2 sample buffer at 37°C for 15 min. The samples were analyzed
by SDS-PAGE and visualized by autoradiography.
Coimmunoprecipitation of CFTR with Chaperones
Cells were starved and pulse labeled as described above for the pulse-chase
assay. Lysates were prepared in coimmunoprecipitation buffer with an ATP
regeneration system (PBS, pH 7.4, supplemented with 1% Triton X-100, 5 mM
Mg-ATP, 80 mM phosphocreatine, 500 g/ml creatine phosphokinase and
Complete Protease Inhibitor [Roche Diagnostics]) and precleared by centrif-
ugation at 20,000 rpm for 10 min in an Allegra 64R centrifuge (Beckman
Coulter, Fullerton, CA). The cleared lysates were split in to three reactions
and then incubated at 4°C for 1 h with rabbit polyclonal -CFTR antibody
directed against the N terminus (provided as a kind gift from Dr. K. Kirk),
rabbit polyclonal -calnexin antibody (Nventa Biopharmaceuticals) or rabbit
-hsc/p70 antibody (Nventa Biopharmaceuticals). This was followed by the
addition of 25 l of a 70% protein G slurry, and incubations with beads were
carried out for 30 min. Protein G pellets were washed twice with PBS-Tr
buffer (PBS supplemented with 1% Triton X-100) and eluted in 25 l of 2
sample buffer. For reimmunoprecipitation, the primary immunoprecipitates
were washed once with PBS-Tr buffer and eluted in 25 l of 2 sample buffer
at 37°C for 15 min. Then, a 20-l aliquot was diluted in 750 l of PBS
supplemented with 1% Triton X-100, 0.2% SDS, and 0.5% bovine serum
albumin. The reimmunoprecipitation was carried out by incubation with 5 l
of polyclonal -CFTR antibody for 1 h and subsequent incubation with 50 l
of a 50% slurry of protein A-Sepharose for 30 min at 4°C. The beads were
washed twice with PBS-Tr supplemented with 0.2% SDS. Immunoprecipi-
tated proteins were eluted in 2 sample buffer at 55°C for 15 min before
loading on 10% gels, and they were visualized by autoradiography.
Limited Proteolysis
Six wells of a six-well plate containing HEK293 cells were transfected with 1 g
each of the indicated plasmids. Where indicated, 5 mM CAS was added to the
media 5 h after transfection. Twenty-four hours posttransfection, the cells were
harvested by citric saline and lysed in PBS-Tr (0.1%) for 1 h at 4°C. Lysates were
cleared by centrifugation at 20,000 rpm for 10 min in an Allegra 64R centrifuge
(Beckman Coulter). Supernatants were removed, and total microgram quantities
of protein were determined by the DC protein determination assay (Bio-Rad).
Cleared cell lysates were diluted in PBS-Tr (0.1%) to make 100-l aliquots of a 2
mg/ml cell lysate solution. Twenty-five l aliquots of trypsin stocks were then
added to each aliquot to reach the indicated final trypsin concentrations. The
cleavage reactions incubated on ice for 15 min, and they were quenched by
addition of Complete Protease Inhibitor (Roche Diagnostics) and trypsin inhib-
itor. Sample buffer was added to a final 1 concentration, and samples were run
on 12.5% SDS-PAGE gels. Gels were transferred to nitrocellulose and probed
with CFTR antibodies as indicated above.
RNAi Analysis
Six-well samples of HEK293 cells were transfected with 100 nM total of
oligonucleotides (oligos) directed at either CHIP (sequence 1, GGAG-
CAGGGCAAUCGUCUG; sequence 2, CCAAGCACGACAAGUACAU),
RMA-1 (sequence 1, GCGCGACCUUCGAAUGUAA; sequence 2, CGGCAA-
GAGUGUCCAGUAU), or a nonspecific control (Dharmacon RNA Technol-
ogies, Lafayette, CO) by using Lipofectamine 2000 (Invitrogen) as a transfec-
tion reagent. Forty-eight hours after transfection cells were transfected a
second time with 1 g of plasmid DNA by using Effectene to express the
indicated CFTR fragments. Cells were harvested 18 h after the second trans-
fection. Sample buffer was added to cell pellets at a final 2 concentration,
samples were sonicated, and then equal microgram amounts of cell lysate (as
determined by the DC Protein Assay) were run on 12.5% SDS-PAGE gels.
Gels were transferred to nitrocellulose and probed with CFTR antibodies.
The calnexin shRNAmir construct (pGIPZ calnexin; V2LHS_150212) and
the nonsilencing pGipZ control (RHS4346) were purchased from Open Bio-
systems (Huntsville, AL), and 2 g of plasmid was transfected per six-well by
using Lipofectamine 2000 as a transfection reagent. Eighteen hours after
transfection, puromycin (10 g/ml) was added to the HEK293 cells to select
for those cells that took up the pGIPZ plasmids. Cells were grown in puro-
mycin-containing media for 5 d, and then a second transfection was per-
formed with Effectene reagent to introduce the indicated CFTR plasmids.
Eighteen hours later, the cells were harvested, and equal microgram quanti-
ties of cell lysates (as determined by the DC Protein Assay) were run on 10%
SDS-PAGE gels.
RESULTS
Calnexin Acts Transiently at a Late Stage Folding Event
of WT CFTR
To identify the calnexin-mediated steps in CFTR folding, we
first compared the timing of calnexin and Hsp70 binding
and release to the newly synthesized and immaturely gly-
cosylated B-form of [35S]CFTR in pulse-chase experiments
(Figure 1). The B-form of CFTR was detected in coimmune-
precipitable complexes with calnexin immediately after the
labeling period. Yet, even though a large pool of CFTR
remained in the ER after a 45-min chase incubation, there
was a dramatic reduction in the levels of calnexin:CFTR
complexes. In contrast, the relative quantity of the B-form of
CFTR that could be coimmuneprecipitated with Hsp70 did
not change dramatically over the course of the 90-min chase
period. Thus, complexes formed between Hsp70 and the
B-form of CFTR were not as transient as those observed with
calnexin. These data suggest that calnexin acts in a “hit-and-
run” manner in which it binds CFTR to facilitate a specific
step in the folding pathway, and then it releases the CFTR
molecule before completion of its global folding.
To identify the step in the CFTR folding pathway facili-
tated by calnexin, we determined its ability to bind different-
length CFTR fragments that resemble biogenic intermedi-
ates (Figure 2A). Again for comparison, we also analyzed
the binding of Hsp70 to the same CFTR fragments. Overall,
this analysis performed with the CFTR fragments provides
insight as to the stages of CFTR biogenesis at which chap-
erone action is required. However, because these fragments
are overexpressed in a heterologous system, it may be that
Figure 1. Calnexin–CFTR complexes are short lived in comparison
with Hsp70–CFTR complexes. (A) HEK293 cells were transiently
transfected with WT CFTR, starved for 20 min, labeled with [35S]me-
thionine, and chased for the indicated amounts of time. Cells were
lysed in PBS-Tr (1%) and immunoprecipitations were performed
with -CFTR, -calnexin, or -Hsp70 antibody as indicated. Results
shown are representative of one experiment, but trends were iden-
tical when the experiment was repeated three individual times. (B)
The amount of CFTR bound by either calnexin or Hsp70 was quan-
tified by laser densitometry and normalized to the amount of CFTR
B band remaining at that time point.
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the absolute requirement for chaperones is higher than what
would be seen with native protein. Direct CFTR immuno-
precipitations under denaturing conditions indicate that the
expression of each CFTR construct was similar, except CFTR
1-1162 accumulated to a slightly lower level (Figure 2B).
Coimmunoprecipitations with chaperones under native
buffer conditions were carried out from the same cell lysates
as the direct immunoprecipitations. The quantity of CFTR
fragment coimmunoprecipitated with the indicated chaper-
one was normalized to the total quantity of the respective
fragment and expressed as a percentage in relation to the
fragment with the highest complex formation (Figure 2, D
and E). Calnexin is only detected in complex with CFTR
after MSD2 has been translated, as would be expected from
the glycosylation site found in MSD2. Calnexin displayed
the highest affinity for CFTR 1-1172, and upon synthesis of
NBD2 the ability to isolate CFTR:calnexin complexes was
strongly reduced. On three repeats of the coimmunoprecipi-
tation experiments, the percentage of increase in calnexin
binding from the 837 fragment to the 1172 fragment aver-
aged at 73% (p  0.005), and the decrease in calnexin bind-
ing from the 1172 fragment to full-length CFTR averaged at
30% (p  0.06). These data suggest that the point at which
calnexin is required to act is after translation of the MSD2
but precedes the translation of the NBD2 domain. In addi-
tion, the presence of NBD2 seems to enhance the ability of
CFTR translation intermediates to progress past the point
where calnexin binding sites are exposed.
In contrast, Hsp70 bound a greater percentage of CFTR
1-837, which comprises MSD1, NBD1, and the R domain,
than any of the other fragments tested. It seems that the
addition of the R domain greatly contributes to this affinity
because a significantly lower percentage of CFTR 1-642,
which lacks the R domain, was found in complex with
Hsp70 (average of 40% less 1-642 than 1-837 found in com-
plex with Hsp70; p 0.05). On addition of the MSD2 do-
main, CFTR 1-1162 as well as CFTR 1-1172 are able to form
a structure that is not readily recognized by Hsp70 (70%
decrease for 1-1172 in comparison with 1-837; p  0.005), but
Hsp70 binding increases once again after exposure of the
NBD2 domain (average 41% increase for full-length CFTR
binding to Hsp70 in comparison with 1-1172; p  0.05).
These data indicate that Hsp70 is able to bind each of the
cytosolic domains of CFTR but that the affinity for the NBD1
and R domains is decreased after translation of MSD2. This
suggests a folding pathway for CFTR in which translation of
MSD2 results in a compact folded structure in which Hsp70
is no longer necessary to stabilize the exposed NBD1 and R
domains. These data suggest that Hsp70 is involved in the
folding of cytosolic regions of CFTR that are localized in
both the N and C terminus, whereas calnexin binds MSD2
and facilitates a folding reaction that does not require NBD2.
Yet, the presence of NBD2 seems to enhance the ability of
CFTR to progress past the calnexin-dependent step.
Calnexin Promotes Interactions between MSD1 and MSD2
of CFTR
To test the concept that calnexin acts in CFTR assembly
before NBD2 synthesis, we compared the effect of CAS on
the biogenesis of CFTR, CFTRF508, and CFTR 1-1172 (Fig-
ure 3, A–F). CFTR 1-1172 lacks NBD2 but folds to a confor-
mation that passes ERQC and functions at the cell surface as
a Cl channel (Cui et al., 2007). Treatment of cells with CAS
inhibits calnexin-dependent protein folding reactions (Ham-
mond et al., 1994; Ellgaard and Helenius, 2003) and blocks
calnexin binding to CFTR (Figure 3D). We confirmed that
treatment of cells with CAS decreases the folding efficiency
Figure 2. Calnexin preferentially binds late folding intermediates of
CFTR, whereas Hsp70 binds both early and late folding intermediates.
(A) Domain structures of CFTR constructs used for coimmunoprecipi-
tations in this figure and in later figures. Individual domains of CFTR
are color-coded to indicate which domains are found in each construct.
(B and C) HEK293 cells were transfected with the indicated CFTR
plasmids, labeled with [35S]methionine and lysed in PBS-Tr (1%). Cell
lysates were precleared and then split into three reactions and immu-
noprecipitated with either polyclonal -CFTR N-terminal antibody (B)
or -Hsp70 or -calnexin antibody (C) as described in Materials and
Methods. Hsp70 and calnexin immunoprecipitations were then sub-
jected to a secondary reimmunoprecipitation with -CFTR antibody;
these re-IPs are shown in (C). (D and E) To determine the relative
amount of the CFTR fragment that interacts with calnexin (D) or Hsp70
(E), CFTR levels in the direct and reimmunoprecipitations were quan-
tified by laser densitometry. The amount of CFTR fragment that was
coimmunoprecipitated with the chaperone was normalized to the in-
put levels of that specific fragment (as determined by the direct im-
munoprecipitation with CFTR antibody), and then all values were
expressed as a percentage of that fragment showing the highest affinity
for that specific chaperone. The data in B and C of this figure are from
one representative experiment; however, average values from three
independent experiments are shown in D and E.
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of WT CFTR by 50% as indicated by the decreased matu-
ration to C band from 32% after 2 h to 16% (Figure 3A). The
inhibition in C band maturation was repeatedly observed
after addition of CAS (n  4; average 44% decrease in
maturation; p  0.05) and ranged in efficacy from 30 to 60%.
CFTR folding efficiency is reduced by 50% in cells cultured
from calnexin / mice, so CFTR-folding defects caused by
CAS treatment of cells are nearly identical to those observed
when calnexin is absent form the ER (Okiyoneda et al., 2008).
Consistent with results from studies with calnexin /
mice (Okiyoneda et al., 2008), but in contrast to previous
reports (Farinha and Amaral, 2005), CAS had little detect-
able effect on the degradation of WT or F508 CFTR (Figure
3B). More importantly, CAS reduced the biosynthetic mat-
uration of CFTR 1-1172 to the C-form by approximately
threefold (Figure 3, E and F). Calnexin therefore seems to
facilitate a folding step that involves interaction between
MSD2 and amino-terminal regions of CFTR. Calnexin may
facilitate CFTR folding by stabilizing MSD2 and thereby
promoting formation of proper contacts between MSD1 and
MSD2. To test this model, we took advantage of the obser-
vation that split CFTR fragments that individually contain
the N- and C-terminal subdomains assemble into an ion
channel when expressed in trans (Chan et al., 2000). N-
terminal CFTR fragments containing MSD1, NBD1, and the
R domain fold to a conformation that has a long half-life and
accumulates at high levels when expressed alone or in trans
with CFTR 837-1480 (Ostedgaard et al., 1997; Xiong et al.,
1997; Meacham et al., 1999). However, when CFTR 837-1480
is expressed alone it accumulates at low levels as an imma-
turely glycosylated species (Figure 4A). Yet, upon coexpres-
sion with CFTR 1-837 a severalfold increase in total CFTR
837-1480 accumulation and a pool of its maturely glycosy-
lated C-form were detected. The identity of the B-band of
CFTR 837-1480 as the ER-localized immaturely glycosylated
protein, and the C-Band as the post-Golgi, maturely glyco-
sylated form was confirmed by endoglycosidase H (EndoH)
and peptide N-glycosidase F (PNGaseF) digestion (Figure
4B). BFA, an inhibitor of ER-to-Golgi trafficking, also
blocked the CFTR 1-837–dependent glycolytic maturation of
CFTR 837-1480 and allows for better visualization of the
stabilization of the 837-1480 fragment that occurs upon co-
expression with CFTR 1-837 (Figure 4A). Chemical interfer-
ence with calnexin binding by addition of CAS resulted in
decreased levels of CFTR 837-1480 (Figure 4A). Further-
more, CAS also prevented the CFTR 1-837–dependent in-
crease in CFTR 837-1480 levels and glycolytic maturation of
CFTR 837-1480 was no longer observed (Figure 4A). In the
presence of CAS, treatment with the proteasomal inhibitor
ALLN restores the steady state levels of CFTR 837-1480,
thereby indicating that misfolding events caused by inhibi-
tion of calnexin interactions are recognized by the ubiquitin
proteasome system (Figure 4C).
Because CAS is a chemical inhibitor of the glucosidase I
and II enzymes, we also used RNAi techniques to confirm
that the above-observed effects were directly due to inhibi-
tion of calnexin binding. A vector encoding a short hairpin
RNA (shRNA) against calnexin was used to decrease the
endogenous calnexin levels, and then the stability of CFTR
837-1480 as well as CFTR fragment assembly was monitored
by expressing CFTR 837-1480 alone or in trans with CFTR
immuneprecipitation and then a secondary reimmunoprecipitation
was performed with rabbit polyclonal -CFTR. Products of immu-
noprecipitations were eluted in SDS sample buffer and analyzed by
SDS-PAGE and autoradiography.
Figure 3. Inhibition of calnexin through treatment with CAS inhibits
folding of wild-type CFTR. HEK293 cells transiently transfected with
pcDNA3.1-CFTR (A), pcDNA3.1-F508-CFTR (B), or pcDNA3.1-CFTR
1-1172 (E) were preincubated for 1 h in the absence or presence of 5
mM CAS, and then starved, labeled with [35S]methionine, and chased
for the indicated amounts of time. The cells were then lysed and
incubated with -CFTR rabbit polyclonal antibody. Results were quan-
tified by densitometry and graphed in C and F. (D) Control samples
were used to indicate the level to which CAS treatment inhibited
calnexin–CFTR interactions. Samples were first subjected to a calnexin
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1-837 (Figure 4D). In agreement with the CAS data, upon
calnexin knockdown we observed a severalfold decrease in
the stability of 837-1480, and in the 1-837–dependent forma-
tion of 837-1480 C band. The level of destabilization and
inhibition of fragment assembly seemed to correlate well
with the level of calnexin knockdown achieved. Overall,
these data suggest that calnexin plays an important role in
CFTR folding, and these studies show that one of its func-
tions is to stabilize MSD2, which is required for proper
assembly of the MSD1/MSD2 complex.
Mechanism of F508-induced Misfolding of CFTR
The common F508 mutation in CFTR causes defective as-
sociation of MSD1 and MSD2 (Chen et al., 2004). Data ob-
tained with CAS show that inhibition of MSD assembly
leads to instability of the second half of the CFTR molecule.
Thus, we investigated the possibility that the F508 muta-
tion causes similar defects in MSD2 stability. This is an
important question because contact formation between F508
and intracellular loops exposed by MSD2 seems to be critical
for CFTR assembly (Mendoza and Thomas, 2007; Serohijos et
al., 2008). To determine whether the misfolding events
caused by the deletion of F508 were similar to those caused
by CAS-induced instability of CFTR, we coexpressed CFTR
1-837F508 with CFTR 837-1480. Normally, coexpression of
the wild-type forms of the two CFTR halves results in both
the stabilization of 837-1480 as well as the maturation of
CFTR 837-1480 to a maturely glycosylated C form (Figures
4A and 5A). However, expression of CFTR 1-837F508 in
trans with CFTR 837-1480 results in the stabilization of CFTR
837-1480, but not in glycolytic maturation (Figure 5A). These
results indicate that the F508 residue is not required for
CFTR 1-837 to stabilize CFTR 837-1480. Yet, F508 seems
essential for downstream folding events that enable CFTR
837-1480 to fold and escape the ER.
How deletion of F508 causes defects in CFTR folding is
not clear and during the course of this experiment, we
observed that the deletion of F508 resulted in a dramatic
decrease in the steady-state levels of CFTR 1-837 (Figure
5A). Therefore, the F508 residue seems to be important for
the proper folding of CFTR 1-837, and defects in this process
seem to prevent proper folding of C-terminal regions in
CFTR. Based on these data, we sought to pinpoint the first
step at which the F508 mutation exerts its effect on CFTR
folding, and we analyzed the stability of wild-type and
mutant CFTR fragments by pulse chase (Figure 5B). We first
looked at the effect of deletion of F508 from a CFTR fragment
consisting of amino acids 1–653, which stops at the NBD1
boundary before inclusion of the regulatory extension
(Lewis et al., 2004; Baker et al., 2007). We found that CFTR
1-653 F508 accumulated to slightly lower levels than the
wild-type fragment immediately after the labeling period
(i.e., there was 27% less of 1-653 F508 in comparison with
WT 1-653 at t  0). Furthermore, deletion of F508 resulted in
a slight increase in the rate of degradation of this fragment
over the chase period such that there was 37% of total
wild-type protein remaining after the 90-min chase in com-
parison to 19% of the 1-653 F508 protein remaining. How-
ever, the defect observed with CFTR 1-653F508 did not
seem to match the severity of the defect observed with the
full-length protein (Ward and Kopito, 1994; Ward et al., 1995;
Meacham et al., 2001) or with the steady-state levels of CFTR
1-837 F508 (Figure 5A). Therefore, to identify other regions
of CFTR that are affected by deletion of F508, we performed
pulse-chase analysis on fragments containing the NBD1 plus
the regulatory extension (RE) (CFTR 1-673) as well as a
fragment containing the complete R domain (1-837) (Baker et
al., 2007). First of all, we observed that as we included more
of the R domain, the protein became more stable over the
chase period (37% of 1-653 remained after 90 min, 53% of
1-673, and 71% of 1-837). Second, the pattern observed with
CFTR 1-673 was very similar to that observed with 1-653 in
which deletion of F508 results in slightly decreased protein
levels at t  0 of the chase (a 24% decrease in total levels of
Figure 4. Calnexin interactions are required for effi-
cient assembly of MSD1 and MSD2. (A and C) Assembly
of CFTR membrane spanning domains. HEK293 cells
were transfected with CFTR 1-837 or CFTR 837-1480,
and cells were either treated 5 h posttransfection with 10
g/ml BFA or 5 mM CAS, or 18 h posttransfection with
200 M ALLN where indicated. Cells were harvested
24 h after transfection, and cell lysates subjected to
Western analysis with CFTR N-terminal or NBD2 spe-
cific antibodies. Maturely glycosylated 837-1480 is indi-
cated as C band, and immaturely glycosylated 837-1480
is indicated as B band. Tubulin is used as a loading
control. (B) HEK293 cells were transfected with pcDNA
CFTR 1-837 and pcDNA CFTR 837-1480, and harvested
24 h after transfection. Cells were then lysed in 1% SDS
with 0.1 mM B-mercaptoethanol, sonicated, and incu-
bated at 37°C for 10 min. Samples were then diluted
fivefold into reaction buffer (5% Triton, 100 mM so-
dium phosphate, pH 5.5, for Endo H or 100 mM
sodium phosphate, pH 7.6, for PNGaseF), the indi-
cated enzyme (PNGaseF or EndoH) was added, and
samples were incubated overnight. Sample buffer was
added to a final 1 concentration, and samples were
run on 10% SDS-PAGE gels. Western blots were per-
formed with the -NBD2 CFTR antibody. Bands B
and C represent the immature and maturely glycosy-
lated forms, respectively, and band A represents the
nonglycosylated form of CFTR 837-1480. (D) HEK 293
cells were transfected with the calnexin shRNAmir
construct or the nonsilencing control as indicated in Materials and Methods. Cell lysates were subjected to Western Blot analysis with
the indicated antibodies.
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CFTR 1-653 at t  0), as well as a slight increase in degra-
dation rates (53% WT 1-653 protein remaining after 90-min
chase vs. 40% of mutant 1-653F508 protein remaining). Yet,
consistent with what we observed in CFTR fragment assem-
bly assays, there was a drastic decrease in the accumulation
of 35S-labeled CFTR 1-837F508 (a 80% decrease in total
levels at t  0). The pool of 1-837F508 protein that did
accumulate during the labeling period also seemed to have
an increased rate of degradation such that 71% of the wild-
type 1-837 protein remained after the 90-min chase, in com-
parison with 53% of the mutant 1-837F508. The simplest
interpretation of these data are that the F508 deletion causes
a folding defect that only modestly enhances that ability of
ERQC factors to select CFTR fragments that contain MSD1
and NBD1 for degradation. Yet, the F508 deletion dramati-
cally disturbs the folding of MSD1, NBD1, and the R-domain
into a stable complex, which causes a large pool of
CFTRF508 to be selected for proteasomal degradation.
To confirm that the dramatically reduced levels of the
CFTR1-837 fragment observed upon deletion of F508 are
resultant from its premature proteasomal degradation, we
first examined the steady-state levels of wild type and mu-
tant F508 forms of this protein in the absence and presence
of the proteasome inhibitor ALLN (Figure 5C). In the pres-
ence of ALLN, steady-state levels of CFTR 1-837F508 were
increased by 50%. Second, small interfering RNA knock-
down of the E3 ubiquitin ligase RMA1, which is proposed to
detect defects in CFTR folding cotransationally (Younger et
al., 2006), led to an average 135% increase in accumulation of
CFTR 1-837F508 in comparison with an average 33% in-
crease for the wild-type 1-837 protein (values are averages
from 3 trials). The drastic increase seen with 1-837F508 in
comparison with 1-837 was statistically significant, with a p
value 0.05, and it is in agreement with data previously
published showing that CFTR was more sensitive to RMA1
after deletion of the F508 residue (Younger et al., 2006). In
contrast, knockdown of the E3 ubiquitin ligase CHIP, which
seems to primarily recognize later folding defects (Younger
et al., 2006), only had minimal effects on the accumulation of
WT 1-837 or 1-837 F508 (14 and 11% average increases,
respectively). Thus, a CFTRF508 folding defect that occurs
before calnexin action is related to misassembly of N-termi-
nal regions of CFTR, and these defects are primarily de-
tected by the RMA1 E3 ubiquitin ligase complex.
Global Misfolding of CFTR as Assayed by Limited
Proteolysis
Next, limited proteolysis was utilized to probe the global
structure of CFTR when calnexin-dependent folding steps
were inhibited (Zhang et al., 1998; Cui et al., 2007). Then, we
compared the conformation of CFTR whose folding was
arrested by loss of calnexin binding with the conformation
of disease-related CFTR mutant proteins that contain point
mutations in different subdomains. Proteolytic fragments of
CFTR generated by adding increasing concentrations of
trypsin to detergent-solublized cell extracts were detected
by Western blot with an antibody directed against the N-
terminal tail or NBD2 (Figure 6). The N-terminal tail anti-
body was able to detect two major trypsin cleavage products
of CFTR. The first major cleavage product is a band of 72
kDa, which runs just below the 1-837 fragment composed of
the MSD1, NBD1, and R domain. The next cleavage product
is a band of 40 kDa, which corresponds to a cleavage
immediately preceding NBD1. Inhibition of calnexin bind-
ing to CFTR did not significantly affect the cleavage pattern
detected by the N-terminal antibody, but there was a notice-
able increase in the sensitivity of both the 72- and 40-kDa
Figure 5. Folding defects caused by introduction of the F508
mutation. (A) HEK293 cells were transfected with CFTR 1-837,
CFTR 1-837F508, or CFTR 837-1480 where indicated and cultured
for 24 h. Steady-state levels were then determined by Western blot.
(B) HEK293 cells were transfected with the indicated CFTR plas-
mids, and 24 h after transfection, the cells were pulse labeled with
[35S]methionine, chased for the indicated periods, and lysed in
PBS-Tr (1%). Cell lysates were then immunoprecipitated with a
-CFTR N-terminal antibody and visualized by SDS-PAGE analysis
and autoradiography. (C) HEK293 cells were transfected with CFTR
1-837 or CFTR 1-837 F508, and 18 h after transfection they were
treated with 200 M ALLN where indicated. Western blot analysis
was performed with the CFTR N-terminal antibody (MM1-34). Der-
lin-1 blots were performed to indicate loading controls. (D) Trans-
fections with RNAi oligos and CFTR plasmids were performed as
indicated in the Materials and Methods, cells were lysed in 2 sample
buffer, and equal microgram quantities of protein were run on
SDS-PAGE gels. Western blot analysis was used to determine
steady-state levels of indicated proteins. Tubulin blots were used as
loading controls. Control experiments were performed with over-
expressed FLAG-RMA1 to indicate the efficacy of the RMA1 RNAi
oligos, and endogenous CHIP levels were monitored in response to
RNAi addition through the use of a polyclonal CHIP antibody.
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fragments to digestion. For example, in wild type CFTR, the
40-kDa fragment is stable when trypsin concentrations are
increased from 5 to 25 g/ml (see boxed fragments in Figure
6A, top). However, upon treatment with CAS, this fragment
increases in sensitivity to trypsin. These data are consistent
with the notion that calnexin-dependent formation of inter-
domain contacts between helices in MSD1 and MSD2 is
required for proper folding of both membrane-inserted and
cytosolic domains of full-length CFTR.
The NBD2 antibody was able to detect three major cleav-
age products in WT CFTR; an 80-kDa band, a 35-kDa
band, and a 26-kDa band. Based on molecular weight, these
bands likely correspond to cleavage events toward the end
of the R domain, near the end of the MSD2 domain, and
right at the beginning of the NBD2 domain, respectively. We
noticed that the band corresponding to the NBD2 domain
existed as a doublet separated by 3 kDa (indicated as
NBD2 and NBD2*), with the top band being the dominant
one for WT CFTR. However, upon addition of CAS, we
noticed a shift in the ratio of these bands, such that NBD2*
increased in prominence (see boxed fragments in Figure 6A,
bottom). These data suggest that improper MSD assembly
leads NBD2 folding to become arrested. In the absence of
proper calnexin function, it seems that NBD2 still collapses
to a protease-resistant state, but it fails to bury a small loop
that can now be cleaved by trypsin and this gives rise to
NBD2*.
We next compared the trypsin proteolysis patterns of
misfolded CFTR from CAS-treated cells with the patterns
observed from CFTRF508, CFTRG91R, and CFTR N1303K,
which contain mutations localized to the NBD1, MSD1, and
NBD2 domains, respectively (Osborne et al., 1992; Xiong et
al., 1997). Similar to what we observed upon CAS treatment,
the sizes of the N-terminal fragments produced by trypsin
digestion of the CFTRF508 and CFTRG91R mutants did
not change significantly, but a significant increase in the
sensitivity of the 40-kDa fragment to digestion by 25 g/ml
trypsin was observed (Figure 6B). In contrast, mutation of
N1303K in NBD2 did not drastically affect the stability of
CFTR N-terminal fragments. Yet, the protease resistance
of NBD2 was reduced to a greater extent with the three
mutant CFTR proteins than what we observed with CAS-
treated CFTR. In each mutant, there was a decrease in the
protease resistance of the NBD2 band, and the smaller
NBD2* band became the more prevalent band of the two
(see boxed fragments in Figure 6B, bottom). This is in agree-
ment with results published by Zhang et al. (1998) in which
they demonstrate that the F508 mutation results in disrup-
tion of the NBD2 domain. Yet, the fact that the G91R muta-
tion, and to a lesser extent, inhibition of calnexin function
also hinder NBD2 folding suggests that general disruption
of MSD assembly prevents proper folding of NBD2. These
data suggest the calnexin helps facilitate the cooperative
folding of CFTR through promoting interdomain contacts
that facilitate folding of both N- and C-terminal domains.
DISCUSSION
The data presented herein define the point at which calnexin
acts in the CFTR folding pathway and help to delineate the
mechanism of misfolding events that result in CFTR’s rec-
ognition by the ERQC pathway. We have found that caln-
exin action is essential for both stabilizing the C-terminal
half of CFTR as well as for promoting proper association
between MSD1 and MSD2. Calnexin-dependent association
of CFTR’s membrane regions is important for proper folding
of CFTR’s N-terminal domains and complete collapse of the
NBD2 domain. Interestingly, calnexin action juxtaposes a
critical point in the CFTR folding pathway, as disease caus-
ing mutations such as F508 disrupt CFTR folding in similar
ways. For example, deletion of F508 has also been shown to
block membrane spanning domain assembly (Chen et al.,
2004) and NBD2 folding (Du et al., 2005). Furthermore, we
have found that these late folding defects caused by the
Figure 6. Limited Proteolysis of WT CFTR and CFTR mutants. (A and B) 	293 cells were transiently transfected with the indicated
plasmids, and 5 h after transfection, they were treated with 5 mM CAS where indicated. Twenty-four hours after transfection cells were
harvested and lysed in PBS-Tr (0.1%). Equal microgram quantities of cleared cell lysates were exposed to the indicated concentrations of
trypsin for 15 min on ice. Cell lysates were then run on 12.5% gels and subjected to Western Blot analysis with the indicated antibody (either
-N-terminal CFTR or -NBD2 CFTR).
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F508 mutation are accompanied by an early folding defect
that becomes evident after translation of the R domain and
is sensed by the RMA1 ubiquitin ligase.
The point at which calnexin acts in the CFTR folding
pathway was previously unknown, and it was not immedi-
ately obvious, considering that the lectin domain of calnexin
is localized to the ER lumen, where little of the CFTR protein
is found. However, based on our data we now propose a
model in which the binding of calnexin to the sugars at-
tached to extracellular loop 4 of MSD2 acts to stabilize or
orient this domain in such a manner as to promote produc-
tive interactions with MSD1 (Figure 7). Structural studies of
the related ABC transporter protein Sav1866 show that the
transmembrane domains adopt a complex structure in
which transmembrane domains from MSD1 cross-interact
with transmembrane domains of MSD2 to form a two-
winged pore structure (Dawson and Locher, 2006). A three-
dimensional structural model of CFTR, which is based on
the Sav1866 structure, predicts that transmembrane (TM)
helices 1 and 2 of CFTR pack next to TM helices 9, 10, 11, and
12 to make one wing of the pore, whereas TM helices 7 and
8 pack next to TM helices 3, 4, 5, and 6 to form the other wing
of the pore (Serohijos et al., 2008). Because the CFTR glyco-
sylation sites are found in the extracellular loop connecting
TM 7 and 8, we propose that calnexin binds this segment of
CFTR to assemble TM 7 and 8 into the proper wing of the
pore (Figure 7). The need for proper folding and assembly of
the CFTR transmembrane domains is highlighted by the
large number of disease-causing mutations found in TM
domains. There are 625 missense cystic fibrosis-causing
mutations identified in CFTR, with 300 of these localized
to transmembrane domains or their connecting extracellular
loops (Cheung and Deber, 2008).
A major defect in CFTRF508 folding predicted by the
Sav1866 structure is defective interaction of NBD1 with a
hydrophobic surface exposed on intracellular loop 4 on
MSD2. Yet, how this defect leads to misfolding and prema-
ture degradation of CFTR is not clear. Data obtained with
split CFTR fragments suggest that regions of MSD2 are not
stably inserted into the ER membrane and that calnexin
binding and association with MSD2 are required to stabilize
MSD1. The F508 deletion leads a fragment of CFTR 1-1162 to
be rapidly degraded and prevents the glycolytic maturation
of a slightly longer fragment CFTR 1-1172 (Younger et al.,
2006; Cui et al., 2007). However, the deletion of F508 from the
CFTR 1-837 fragment does not affect the ability of this N-
terminal fragment to stabilize a C-terminal fragment (CFTR
837-1480), Yet, it does prevent CFTR 1-837 from promoting
the glycolytic maturation of CFTR 837-1480. Thus, in the
context of experiments with CFTR fragment assembly, the
F508 deletion seems to hinder a step in CFTR folding that
occurs after the calnexin-dependent stabilization of MSD2,
which might involve NBD2 (Du et al., 2005).
During the course of our study with split CFTR molecules,
we also observed that compared with CFTR 1-837, the accu-
mulation of CFTR 1-837F508 was dramatically reduced.
Reductions in CFTR 1-837F508 seemed to result from its
misfolding and selection for proteasomal degradation by the
RMA1 E3 ubiquitin ligase. The F508 deletion caused a mod-
est decrease in the stability of CFTR 1-653, an MSD1-NBD1
fragment, but the presence of the complete R-domain re-
sulted in a much more dramatic defect. It may be that the
1-653F508 fragment misfolds but is lacking a recognition
motif for ER QC factors, which then prevents the severe
destabilization effect observed with 1-837F508. Another
likely possibility is that the deletion of the F508 residue
affects the interaction of the R domain with other regions of
CFTR. The R domain is thought to be largely disordered
(Ostedgaard et al., 2000), but it contains ordered segments of
helical structure (Baker et al., 2007), and it has been shown to
interact directly with both the NBD1 domain (Baker et al.,
2007), and with the N-terminal tail of CFTR (Naren et al.,
1999). Translation of the R-domain is also important in en-
suring that N-terminal regions of CFTR achieve a compact
folded structure that can no longer be recognized by the
Hsp40 Hdj-2 (Meacham et al., 1999). Because the F508 resi-
due is localized to NBD1, it is possible that the reduced
stability of 1-837F508 is due to a disruption of MSD1–
NBD1–R domain interactions, which then results in recog-
nition by the RMA1 E3 machinery.
The conglomeration of current data suggest a model in
which interdomain contacts are essential for the folding of
CFTR, and when disrupted result in specific misfolding
events that are then recognized by the ERQC machinery.
There seems to be an interplay between the ER lumenal
chaperone system and the cytosolic chaperone system that
allows for the proper folding and assembly of membrane
spanning domains and cytosolic domains of CFTR. We have
also found that MSD assembly is a critical aspect of CFTR’s
folding pathway, because it is disrupted by a variety of
mechanisms, including inhibition of calnexin interactions, or
introduction of disease-causing mutations such as F508.
Because deletion of F508 causes defects in CFTR folding that
occur at early and late stages of CFTR assembly, drugs that
correct CFTR folding defects might need to act at multiple
steps in CFTR biogenesis.
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Figure 7. Model of calnexin action in CFTR folding. Calnexin is
shown binding to CFTR through the glycosylation sites found in the
fourth extracellular loop between TM helices 7 and 8. This binding
is proposed to orient TM 7/8 into the proper wing of the CFTR
two-winged pore structure. CFTR TM helices are represented by
cylinders with MSD1 TM helices colored light gray and MSD2
helices colored dark gray. The number of the TM helix is indicated
at the top of each cylinder.
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